Treats relapsing forms of multiple sclerosis (MS). ANDA 210402, held by Amneal Pharmaceuticals. Dimethyl Fumarate.
As of Nov 21, 2026, ANDA 210402 (Dimethyl Fumarate), held by Amneal Pharmaceuticals, was first approved by FDA on Sep 24, 2020, with 6 approved supplements and 0 published complete response letters.
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2020 | Original application | Approved |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Aug 8, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 8, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 8, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 8, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 8, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 8, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 24, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters